Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel

Reese ES, Daniel Mullins C, Beitelshees AL, Onukwuha E

**Record Status**
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

**Bibliographic details**

**PubMedID**
22461122

**DOI**
10.1002/PHAR.1048

**Original Paper URL**

**Indexing Status**
Subject indexing assigned by NLM

**MeSH**
Acute Coronary Syndrome /drug therapy; Aryl Hydrocarbon Hydroxylases /genetics; Cardiovascular Diseases /drug therapy; Computer Simulation; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Trees; Drugs, Generic /economics; Genotype; Hemorrhage /chemically induced /economics; Humans; Models, Economic; Models, Statistical; Myocardial Infarction /drug therapy; Piperazines /adverse effects /economics /therapeutic use; Platelet Aggregation Inhibitors /adverse effects /economics /therapeutic use; Prasugrel Hydrochloride; Thiophenes /adverse effects /economics /therapeutic use; Thrombolytic Therapy /economics; Ticlopidine /adverse effects /analogs & derivatives /economics /therapeutic use

**AccessionNumber**
22012028294

**Date bibliographic record published**
16/10/2012